VCA Inc (WOOF) was Resumed by BofA/Merrill to “Buy”. BofA/Merrill advised their investors in a research report released on Sep 29, 2016.
On the company’s financial health, VCA Inc reported $0.87 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.82. The company had revenue of $653.49 million for the quarter, compared to analysts expectations of $637.18 million. The company’s revenue was up 19.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS.
VCA Inc closed down -0.33 points or -0.49% at $67.1 with 6,32,157 shares getting traded on Tuesday. Post opening the session at $67.5, the shares hit an intraday low of $66.92 and an intraday high of $68.85 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Sep 19, 2016, Arthur J Antin (COO & Senior VP) sold 34,000 shares at $69.03 per share price. According to the SEC, on Sep 8, 2016, Josh Drake (President, Antech Diagnostics) sold 14,584 shares at $72.01 per share price. On Sep 6, 2016, Tomas W Fuller (CFO, VP & Secretary) sold 47,544 shares at $70.59 per share price, according to the Form-4 filing with the securities and exchange commission.
VCA Inc. is a national animal healthcare company operating in the United States and Canada. The Company operates in two segments: animal hospital and laboratory. The Company provides veterinary services and diagnostic testing to support veterinary care and also sells diagnostic imaging equipment and other medical technology products and related services to the veterinary market. The Company provides communication marketing solutions and other services to the veterinary community. The Company’s animal hospital offer general medical and surgical services pharmaceutical products and performs pet wellness programs. The Company’s communication and marketing solutions business provides services to veterinary practices pharmaceutical manufacturers and the pet owning community. The Company’s network of veterinary diagnostic laboratories provides sophisticated testing and consulting services.